Table 2. Diagnosis of all hospitalized patients with infectious diseases and their region of origin during the two study periods.
| Diagnoses | n* | % of all hospitalized patients$ | % of hospita-lized patients with infection | Regions of origin |
|---|---|---|---|---|
| 2004/05 | n = 15 | |||
| Tuberculosis | 4 | 8.9% | 50.0% | EMR (n = 1), EUR (n = 2), unknown (n = 1) |
| Bacterial skin infection | 2 | 4.4% | 25.0% | EMR (n = 1), unknown (n = 1) |
| Atypical pulmonary mycobacteriosis | 1 | 2.2% | 12.5% | EUR (n = 1) |
| Viral pulmonary infection | 1 | 2.2% | 12.5% | unknown (n = 1) |
| Exclusion of tuberculosis | 7 | 15.6% | - | EMR (n = 1), EUR (n = 5), WPR (n = 1) |
| 2014/15 | n = 45 | |||
| Malaria (8 M. vivax, 1 M. falciparum) | 9 | 11.1% | 20.4% | AFR (n = 9) |
| Bacterial pulmonary infection | 6 | 7.4% | 13.6% | AFR (n = 4), EMR (n = 1), EUR (n = 1) |
| Chickenpox | 5 | 6.2% | 11.4% | AFR (n = 4), EMR (n = 1) |
| Viral infection not otherwise specified | 5 | 6.2% | 11.4% | AFR (n = 5) |
| Bacterial skin- and soft tissue infection | 5 | 6.2% | 11.4% | AFR (n = 5) |
| ENT infection | 4 | 4.9% | 9.1% | AFR (n = 2), EUR (n = 1), SEAR (n = 1) |
| Influenza | 3 | 3.7% | 6.9% | AFR (n = 1), EUR (n = 1), SEAR (n = 1) |
| Active tuberculosis | 2 | 2.5% | 4.5% | WPR (n = 2) |
| Louseborne relapsing fever | 2 | 2.5% | 4.5% | AFR (n = 2) |
| Septic arthritis | 1 | 1.3% | 2.3% | EUR (n = 1) |
| Meningococcal meningitis | 1 | 1.3% | 2.3% | SEAR (n = 1) |
| Fungal pulmonary infection | 1 | 1.3% | 2.3% | AFR (n = 1) |
| Exclusion of tuberculosis | 1 | 1.3% | - | WPR (n = 1) |
AFR: African Region; AMR: Region of the Americas; EMR: Eastern Mediterranean Region; EUR: European Region; SEAR: South-East Asia Region; WPR: Western Pacific Region; ENT: ear nose throat infection
* number of hospitalized patients with infection;
$ 45 patients hospitalized in 2004/05 and 81 patients hospitalized in 2014/15